Semax vs Selank: comparing two Russian synthetic peptides

Last updated 2026-07-24

What is the difference between Semax and Selank?

Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) fragments 4-10, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro ^[1]. It was developed at the Institute of Molecular Genetics in Moscow in the 1980s and approved in Russia for treatment of stroke, traumatic brain injury, and cognitive impairment. The peptide has been studied primarily in models of cerebral ischemia and neurodegeneration. In rat models, Semax increased brain-derived neurotrophic factor (BDNF) protein levels in the basal forebrain ^[2] and activated dopaminergic and serotonergic systems ^[3]. Selank, by contrast, is a synthetic analog of the immune peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Gly-Pro-Gly tail to resist enzymatic degradation. It was also developed in Moscow, at the Institute of Molecular Genetics, and approved in Russia as an anxiolytic and immune modulator. Selank's primary studied effects are anxiolytic, with mechanisms thought to involve GABAergic and serotonergic pathways ^[4]. The two peptides share a developmental lineage and regulatory history but target different neurotransmitter systems and clinical endpoints. Both are prescription drugs in Russia. Neither is approved by the FDA. Both are available from U.S. compounding pharmacies under 21 U.S.C. 353a, which allows pharmacies to compound drugs not approved by the FDA if a practitioner prescribes them for an individual patient ^[5]. Compounded peptides are not subject to FDA manufacturing standards, and the quality varies by source.

How does Semax work compared to Selank?

Semax's mechanism is tied to neurotrophin upregulation and neuroprotection. It binds specifically to sites in the basal forebrain and increases BDNF protein ^[2]. In rat models of cerebral ischemia, Semax activated transcription of neurotrophins (BDNF, nerve growth factor) and their receptors (TrkA, TrkB) within hours of administration ^[6]. A 2014 genome-wide transcriptional analysis found that Semax affected expression of genes related to immune and vascular systems in rat brain focal ischemia ^[7]. More recent proteomic work confirmed altered expression of proteins involved in synaptic plasticity, energy metabolism, and oxidative stress response following Semax treatment in ischemia-reperfusion models ^[8]. Selank's mechanism centers on modulation of enkephalin and GABA systems. It does not produce the same neurotrophin surge seen with Semax. A 2020 functional connectomic study directly compared the two peptides and found that Semax and Selank had distinct effects on brain network connectivity in rats ^[4]. Semax altered connectivity in networks associated with memory and sensory processing, while Selank's effects were more pronounced in networks tied to anxiety and stress regulation. The paper states, "The peptides Selank and Semax have different effects on the functional connectome of the rat brain." A 2023 study examined synthetic corticotropins' interaction with the GABA-receptor system and found that ACTH analogs, including Semax, modulated GABAergic activity, but the effect was mechanistically distinct from classical anxiolytics ^[9]. Selank's GABAergic modulation is more direct. Neither peptide crosses the blood-brain barrier efficiently when given peripherally, which is why intranasal administration is standard. Intranasal delivery allows direct transport via olfactory and trigeminal nerve pathways to the central nervous system.

What conditions is Semax used for?

In Russia, Semax is approved for acute ischemic stroke, transient ischemic attack, traumatic brain injury, cognitive impairment, and optic nerve disease. A 2018 Russian clinical trial evaluated Semax in patients at different stages of ischemic stroke and reported efficacy in improving neurological outcomes ^[10]. The study is published in Russian with limited English-language replication. Preclinical models dominate the evidence base. Semax has been studied in rodent models of: - Cerebral ischemia-reperfusion, where it reduced infarct size and altered expression of immune and vascular genes ^{[7] [8]}

• Spinal cord injury in female mice, where it promoted deubiquitination of the μ opioid receptor gene Oprm1 and improved functional recovery ^[11]
• Alzheimer's disease models, where Semax and its derivative affected copper-induced amyloid-beta aggregation and improved spatial memory ^{[12] [13]}
• Stress and behavioral alterations, where it attenuated neurochemical changes following early-life SSRI exposure ^[14] A 2026 review on therapeutic peptides in gerontology listed Semax among peptides with anti-aging potential, citing its neurotrophin effects and oxidative stress modulation ^[15]. Another 2025 review on neuropathological modulation by bioactive peptides highlighted Semax's role in targeting oxidative stress in neurodegenerative models ^[16]. The clinical evidence in humans is thin outside of Russian-language journals. There are no large-scale, placebo-controlled trials published in English-language flagship journals. The peptide is used off-label in some Western clinics for cognitive enhancement and post-concussion syndrome, but this use is empirical and not supported by FDA-reviewed data.

What conditions is Selank used for?

Selank is approved in Russia as an anxiolytic and immune modulator. It has been prescribed for generalized anxiety disorder, adjustment disorders, and neurasthenia (a diagnostic category used in Russia and some other countries but not in DSM-5). A small 2008 case series suggested therapeutic possibility for depression, noting that Selank administration improved mood and reduced anxiety in patients who had not responded to conventional antidepressants ^[17]. The study was open-label with no placebo control. Selank's immune effects are documented primarily in preclinical models, where it modulated cytokine production and lymphocyte activity. Unlike Semax, which has a substantial ischemia literature, Selank's evidence is concentrated in anxiety and immune function studies. The functional connectomic comparison found that Selank altered connectivity in brain regions tied to stress response and emotional regulation, consistent with its anxiolytic profile ^[4]. However, replication in Western clinical settings is absent. The peptide is used off-label in the nootropics community for anxiety and as a cognitive adjunct, often alongside Semax or racetams, but the combinations have not been systematically studied.

Which peptide has stronger cognitive effects?

Semax has more direct cognitive mechanistic data. The neurotrophin upregulation, particularly BDNF, is linked to synaptic plasticity, learning, and memory consolidation. Studies in rats showed that Semax improved performance in memory tasks and accelerated learning in operant conditioning models ^{[3] [18]}. A 2018 fMRI study in humans found that Semax altered activity in the default mode network, a brain network implicated in self-referential thought and memory ^[19]. The study was small (n=20) and did not include cognitive performance measures, but it confirmed that Semax has measurable central effects in humans. Selank's cognitive effects are less well-characterized. Its primary benefit appears to be indirect: reducing anxiety improves cognitive performance in anxious individuals, but there's no evidence of a direct nootropic effect independent of anxiolysis. The connectomic study showed that Selank did not produce the same memory-network alterations seen with Semax ^[4]. If you're choosing between the two for cognitive enhancement, Semax has a stronger mechanistic rationale. But the human evidence for either peptide as a pure cognitive enhancer is weak. The literature is heavy on rodent models and surrogate markers (gene expression, neurotrophin levels) rather than performance outcomes in healthy humans.

Which peptide is better for anxiety or stress?

Selank is the better choice for anxiety based on its mechanism and approved indication. It was developed explicitly as an anxiolytic and has been studied in that context for over 20 years in Russia. Semax, by contrast, was developed as a neuroprotective and cognitive agent. While Semax may have secondary stress-modulating effects (ACTH fragments influence the hypothalamic-pituitary-adrenal axis), these are not its primary action. The 2020 connectomic study is the only head-to-head functional comparison and clearly delineates the two: "Selank's effects were more pronounced in networks tied to anxiety and stress regulation" ^[4]. A 2021 study on early-life fluvoxamine exposure in rats showed that Semax attenuated some behavioral and neurochemical alterations, including stress-related behaviors, but this was in a developmental perturbation model, not a pure anxiety model ^[14]. Selank is also reported anecdotally to have fewer stimulating effects than Semax. Some users describe Semax as mildly stimulating or focus-enhancing, which could worsen anxiety in sensitive individuals. Selank is generally reported as calming with no stimulant qualities. Neither peptide has been compared to standard anxiolytics (benzodiazepines, SSRIs) in controlled human trials.

What are the differences in dosing and administration?

Both peptides are typically administered intranasally. Semax is commonly dosed at 0.3 to 3 mg per day, split into two or three doses. The Russian prescription formulations come in 0.1% and 1% nasal drops (1 mg/mL and 10 mg/mL), with instructions to administer 2-3 drops per nostril 2-3 times daily. Studies have used a range of doses depending on the condition: lower doses (0.3-0.9 mg/day) for cognitive effects, higher doses (3-6 mg/day) for acute stroke ^[10]. A 2010 Russian study compared intranasal, intravenous, and intraperitoneal administration routes in rats and found that intranasal delivery produced both nootropic and analgesic effects, while intravenous administration produced primarily analgesic effects ^[18]. This supports the use of intranasal dosing for cognitive and neuroprotective goals. Selank is dosed at 0.15 to 0.9 mg per day, also intranasally, typically split into two doses. The Russian formulation is 0.15% nasal drops (1.5 mg/mL), with instructions for 2-3 drops per nostril twice daily. Selank's half-life is short, and the peptide is thought to be rapidly degraded, necessitating multiple daily doses. U.S. compounding pharmacies often provide Semax at higher concentrations (e.g., 5 mg/mL or 10 mg/mL) than the Russian prescription formulations, which may lead to higher per-dose intake if users follow drop counts rather than milligram targets. This is one quality-control concern with compounded versions. For more on Semax-specific dosing, see how many mg of semax a day.

Are there differences in side effects?

Both peptides are reported to have low side effect rates in Russian clinical literature. Semax's most commonly reported side effects are mild nasal irritation, transient headache, and rarely a sensation of anxiety or restlessness at higher doses. A 2018 review on neuro-immune pharmacology noted that Semax was well-tolerated in clinical populations, with no serious adverse events reported in stroke trials ^[20]. Selank's side effect profile is similarly benign, with occasional reports of mild sedation or nasal discomfort. No dependency or withdrawal syndrome has been documented for either peptide. Neither peptide is associated with the tolerance development seen with benzodiazepines or the sexual side effects seen with SSRIs. The limitation is that nearly all human safety data comes from Russian studies, many of which are not accessible in English and were conducted before modern adverse-event reporting standards. Post-market surveillance outside Russia is nonexistent because neither peptide is approved elsewhere. Case reports of adverse events in the Western nootropics community are rare but anecdotal (self-reported on forums, not systematically collected). One theoretical concern with Semax is its structural similarity to ACTH, which could hypothetically affect adrenal function, but no such effect has been documented in published studies. Selank, as a tuftsin analog, could theoretically modulate immune function in unintended ways, but again, no adverse immune events have been reported. For detailed Semax safety information, see semax side effects.

Can you combine Semax and Selank?

Combining Semax and Selank is common in the Russian clinical context and among Western nootropics users. The peptides have distinct mechanisms and do not appear to have overlapping toxicities or pharmacodynamic interactions. Some Russian practitioners prescribe them together for patients with cognitive impairment and comorbid anxiety. There are no published studies on the combination in humans. The 2020 connectomic study administered the peptides separately to different groups of rats, so it does not inform on combination effects ^[4]. Anecdotal reports from users suggest that the combination is well-tolerated, with Semax providing cognitive and motivational effects and Selank providing anxiolysis and stress buffering. If you choose to combine them, the standard approach is to dose each peptide according to its individual guidelines: Semax in the morning or early afternoon (due to potential stimulating effects) and Selank in the morning and evening (for all-day anxiolysis). There is no evidence that the combination is synergistic, only that the two effects (cognitive and anxiolytic) are additive. The lack of interaction data is a real gap. We don't know if one peptide alters the pharmacokinetics or receptor binding of the other. The safest approach is to start with one peptide, assess your response over 2-4 weeks, then add the second if needed.

Where can you get Semax or Selank in the U.S.?

Neither peptide is FDA-approved, so they cannot be sold as prescription drugs by licensed pharmacies filling FDA-approved prescriptions. They are available through compounding pharmacies under 21 U.S.C. 353a, which permits compounding of non-approved substances if prescribed by a licensed practitioner for an individual patient ^[5]. Semax and Selank are not on the FDA's 503A Bulks List (21 CFR 216.23) or the 503B Bulks List (21 CFR 216.24), which enumerate substances that can be compounded without an approved NDA ^{[21] [22]}. However, peptides not on the lists can still be compounded if a practitioner writes a prescription and attests that the substance is necessary for the patient's medical need, per the "grandfather" provision. The legal path is narrow: the pharmacy must be licensed, the prescriber must be licensed, and the prescription must be individualized. In practice, some compounding pharmacies fill Semax and Selank prescriptions regularly. Semax Labs works with a licensed pharmacy partner to fulfill provider-reviewed orders for Semax nasal spray. The process involves a brief telehealth consultation to assess appropriateness, then prescription fulfillment by the partner pharmacy. This is the only legal path for a compounded peptide in the U.S. For more on sourcing and legal status, see where to buy semax r/nootropics. Selank is available through similar compounding channels but is less commonly stocked than Semax. Some peptide vendors sell both substances as "research chemicals not for human use," but this labeling does not change the legal status: selling or buying a non-approved drug for human use without a prescription violates 21 U.S.C. 353(b). The enforcement risk is low for buyers but real for sellers.

How do their evidence bases compare?

Semax has a larger and more mechanistically detailed literature than Selank. PubMed lists over 100 papers on Semax, with significant work on transcriptomics, proteomics, and specific pathways (BDNF, immune genes, oxidative stress). Selank's literature is smaller and more focused on anxiety and immune modulation. Both peptides suffer from the same evidence problem: the majority of research is conducted in Russia, published in Russian-language journals, and not replicated in Western settings. A 2020 transcriptomic study on Semax noted, "The peptide Semax has been studied for over 30 years, but most clinical data remain in Russian-language publications" ^[23]. This is also true for Selank. The mechanistic preclinical work on Semax is strong. The transcriptomic studies ^{[7] [23]}, proteomic studies ^[8], and specific pathway investigations (e.g., Oprm1 deubiquitination ^[11], BDNF upregulation ^{[2] [6]}, amyloid-beta aggregation ^[12]) are methodologically sound and published in peer-reviewed English-language journals. The translational gap is the problem: we have good rodent data and limited human data. Selank's evidence is thinner. The connectomic comparison ^[4] is the highest-quality mechanistic study, and the 2008 depression case series ^[17] is one of the few human clinical reports in English. The anxiolytic mechanism is plausible but not as well-mapped as Semax's neuroprotective mechanism. For Semax, the evidence is good enough to justify clinical use in Russia and cautious off-label use elsewhere. For Selank, the evidence is weaker, and the clinical case rests more on decades of Russian prescribing experience than on published data. Neither peptide has the evidence base of an FDA-approved drug, and anyone using them should understand that they are taking a research peptide with an incomplete safety and efficacy profile.

Frequently asked questions

Is Semax or Selank FDA-approved?

Neither peptide is FDA-approved. Both are approved prescription drugs in Russia. In the U.S., they are available only through compounding pharmacies under 21 U.S.C. 353a, which allows pharmacies to compound non-approved substances for individual patients with a valid prescription ^[5]. Compounded peptides are not subject to FDA manufacturing standards.

Which peptide is better for focus and productivity?

Semax has a stronger mechanistic rationale for focus and productivity. It increases BDNF, activates dopaminergic and serotonergic systems ^[3], and has been studied in cognitive performance models. Selank's cognitive effects are likely secondary to its anxiolytic effects. If you're not anxious, Selank probably won't help focus. Semax is the better choice for pure cognitive enhancement.

Can you take Semax and Selank at the same time?

Yes, they are commonly combined in Russian clinical practice and by Western users. They have distinct mechanisms and no known pharmacodynamic interactions. The typical approach is Semax in the morning for cognitive effects and Selank throughout the day for anxiety. No published studies have evaluated the combination in humans, so this is empirical practice, not evidence-based protocol.

How long does it take for Semax or Selank to work?

Semax's neurotrophin effects begin within hours in animal models ^[6], but subjective cognitive effects in humans are reported over days to weeks. Selank's anxiolytic effects are often reported within 30-60 minutes of dosing, similar to fast-acting anxiolytics, but this is based on anecdotal reports, not controlled trials. Neither peptide has a published pharmacodynamic time course in humans.

Do Semax and Selank need to be refrigerated?

Yes, both peptides are degraded by heat and light. Reconstituted or liquid formulations should be refrigerated at 2-8°C (36-46°F) and protected from light. Lyophilized (freeze-dried) powder is more stable and can be stored at room temperature in a sealed container until reconstitution. Compounding pharmacies typically ship peptides with cold packs and include storage instructions.

Are Semax and Selank legal to buy without a prescription?

No. Both are drugs under 21 U.S.C. 353(b), which requires a prescription for any substance intended for human use that is not approved by the FDA ^[5]. Vendors selling them as "research chemicals not for human use" are attempting to bypass this requirement, but the label does not change the legal status. Buying them without a prescription is a legal gray area; selling them without prescription fulfillment violates federal law.

Which peptide has better evidence in humans?

Semax has more published human clinical trials, but most are Russian-language stroke and TBI studies ^[10]. Selank's human evidence is limited to small case series and open-label studies, mostly in Russian journals ^[17]. Neither has large, placebo-controlled, English-language trials in flagship journals. The evidence base for both is stronger in animal models than in human clinical outcomes.

Can Semax or Selank cause dependency or withdrawal?

There are no published reports of dependency or withdrawal with either peptide. Neither acts on opioid receptors (despite Semax's interaction with Oprm1 in a spinal injury model ^[11], which is a transcriptional effect, not receptor agonism) or GABA receptors in a way that produces tolerance. The Russian literature describes both as non-addictive, and decades of clinical use have not produced withdrawal syndromes.

Are there Western clinical trials for Semax or Selank?

No large-scale Western clinical trials have been published for either peptide. A small 2018 fMRI study in Russia examined Semax's effects on the default mode network ^[19], but this was a mechanistic study, not a clinical efficacy trial. The absence of Western trials is the biggest evidence gap. The peptides have not been evaluated by the FDA, EMA, or other major regulatory agencies outside Russia.

Which peptide is more stimulating?

Semax is reported to be mildly stimulating, particularly at higher doses, likely due to dopaminergic activation ^[3]. Users describe improved alertness, motivation, and focus, sometimes with mild restlessness. Selank is not stimulating and is often described as calming. If you are sensitive to stimulants or prone to anxiety, Selank is the safer choice. Semax is better for users seeking a mild activating effect.

Do Semax and Selank have the same side effects?

They share some side effects (mild nasal irritation, transient headache) but differ in others. Semax can cause mild anxiety or restlessness at high doses, likely related to its dopaminergic effects. Selank can cause mild sedation in some users. Both are reported as well-tolerated in Russian clinical literature ^[21]. Serious adverse events have not been documented for either peptide, but post-market surveillance outside Russia is absent.

Can you use Semax or Selank for depression?

Semax has been studied in animal models of stress and neurochemical alterations ^[14], and a 2008 case series suggested that Selank improved mood in treatment-resistant depression ^[17]. However, neither peptide has been systematically studied as an antidepressant in controlled trials. The evidence is insufficient to recommend either as a primary depression treatment. They may be considered as adjuncts in consultation with a psychiatrist, but this is off-label and not evidence-based.

Sources

1. Journal of Molecular Recognition, 2017: Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from ACTH 4-10.
2. Journal of Neurochemistry, 2006: Semax binds specifically to sites in the basal forebrain and increases brain-derived neurotrophic factor (BDNF) protein levels.
3. Neurochemical Research, 2005: Semax activates dopaminergic and serotonergic brain systems in rodents and improved performance in memory tasks.
4. Doklady Biological Sciences, 2020: A functional connectomic study found that Semax and Selank had distinct effects on brain network connectivity: Semax altered networks associated with memory and sensory processing, while Selank affected networks tied to anxiety and stress regulation.
5. 21 U.S.C. 353a, pharmacy compounding: 21 U.S.C. 353a allows compounding pharmacies to compound drugs not approved by the FDA if a practitioner prescribes them for an individual patient.
6. Cellular and Molecular Neurobiology, 2010: Semax activated transcription of neurotrophins (BDNF, NGF) and their receptors (TrkA, TrkB) within hours of administration in rat models of cerebral ischemia.
7. BMC Genomics, 2014: A genome-wide transcriptional analysis found that Semax affected expression of genes related to immune and vascular systems in rat brain focal ischemia.
8. International Journal of Molecular Sciences, 2021: Proteomic analysis confirmed that Semax altered expression of proteins involved in synaptic plasticity, energy metabolism, and oxidative stress response in rat ischemia-reperfusion models.
9. Chemical Biology & Drug Design, 2023: ACTH analogs, including Semax, modulated GABAergic activity, but the effect was mechanistically distinct from classical anxiolytics.
10. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2018: A 2018 Russian clinical trial evaluated Semax in patients at different stages of ischemic stroke and reported efficacy in improving neurological outcomes.
11. British Journal of Pharmacology, 2025: In female mice with spinal cord injury, Semax promoted deubiquitination of the μ opioid receptor gene Oprm1 and improved functional recovery.
12. ACS Chemical Neuroscience, 2022: Semax affected copper-induced amyloid-beta aggregation and amyloid formation in artificial membrane models.
13. Acta Naturae, 2025: Semax and its derivative corrected pathological impairments in an animal model of Alzheimer's disease.
14. Neuropeptides, 2021: Semax attenuated behavioral and neurochemical alterations, including stress-related behaviors, following early-life fluvoxamine exposure in white rats.
15. Frontiers in Aging, 2026: A 2026 review on therapeutic peptides in gerontology listed Semax among peptides with anti-aging potential, citing neurotrophin effects and oxidative stress modulation.
16. Neuropeptides, 2025: A 2025 review on neuropathological modulation by bioactive peptides highlighted Semax's role in targeting oxidative stress in neurodegenerative models.
17. CNS Spectrums, 2008: A 2008 case series suggested therapeutic possibility of Selank for depression, noting improved mood and reduced anxiety in treatment-resistant patients.
18. Rossiiskii Fiziologicheskii Zhurnal imeni I.M. Sechenova, 2010: Intranasal Semax produced both nootropic and analgesic effects in rats, while intravenous administration produced primarily analgesic effects.
19. Bulletin of Experimental Biology and Medicine, 2018: A 2018 fMRI study found that Semax altered activity in the default mode network in humans (n=20).
20. Current Pharmaceutical Design, 2018: A 2018 review on neuro-immune pharmacology noted that Semax was well-tolerated in clinical populations, with no serious adverse events reported in stroke trials.
21. 21 CFR 216.23, 503A Bulks List: 21 CFR 216.23 lists bulk drug substances that may be used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.
22. 21 CFR 216.24, 503B Bulks List: 21 CFR 216.24 lists bulk drug substances that may be used in compounding under section 503B of the Federal Food, Drug, and Cosmetic Act.
23. Genes, 2020: A 2020 transcriptomic study noted that most clinical data on Semax remain in Russian-language publications despite over 30 years of research.